X4 Pharmaceuticals, Inc.

NasdaqCM:XFOR 株式レポート

時価総額：US$347.1m

X4 Pharmaceuticals 配当と自社株買い

配当金 基準チェック /06

X4 Pharmaceuticals配当金を支払った記録がありません。

主要情報

n/a

配当利回り

-68.8%

バイバック利回り

総株主利回り-68.8%
将来の配当利回りn/a
配当成長n/a
次回配当支払日n/a
配当落ち日n/a
一株当たり配当金n/a
配当性向n/a

最近の配当と自社株買いの更新

更新なし

Recent updates

ナラティブ更新 • Jun 17

XFOR: Chronic Neutropenia Opportunity Will Drive Future Stock Upside Potential

Analysts have raised their 12 month price target on X4 Pharmaceuticals stock from $10 to $12, citing a more constructive view of the company’s lead program mavorixafor and its potential in the large, underpenetrated chronic neutropenia market. What’s in the News for X4 Pharmaceuticals X4 Pharmaceuticals received European Commission marketing authorization for XOLREMDI (mavorixafor) capsules to treat patients aged 12 and older with WHIM syndrome in the European Union, following a positive opinion from the EMA’s Committee for Medicinal Products for Human Use.
ナラティブ更新 • Jun 03

XFOR: Chronic Neutropenia Opportunity Will Drive Future Upside Potential

Narrative Update on X4 Pharmaceuticals The consensus analyst price target for X4 Pharmaceuticals has moved to $12, with analysts pointing to the potential of lead drug mavorixafor in chronic neutropenia and WHIM syndrome as the main factor in their valuation analysis. Analyst Commentary Bullish analysts are highlighting X4 Pharmaceuticals as a focused rare disease story centered on mavorixafor, with both chronic neutropenia and WHIM syndrome at the core of their views.
ナラティブ更新 • May 20

XFOR: Single Asset CXCR4 Platform Is Poised To Drive Upside

Analysts have lifted their price target on X4 Pharmaceuticals to $11.67 from $8.00, citing a stronger outlook for mavorixafor as a potential first in class oral CXCR4 antagonist in WHIM syndrome and primary chronic neutropenia. They note that the current valuation does not fully reflect its role as the company's key value driver.
ナラティブ更新 • May 04

XFOR: Single CXCR4 Hematology Program Will Drive Future Upside Potential

Analysts have raised their price target on X4 Pharmaceuticals to $12, citing what they view as significant upside potential from mavorixafor as a key value driver for WHIM syndrome and primary chronic neutropenia, along with a current valuation that they see as not fully reflecting this opportunity. Analyst Commentary Recent Street research frames X4 Pharmaceuticals as a focused hematology company, with attention centered on mavorixafor as a potential first in class oral CXCR4 antagonist for WHIM syndrome and primary chronic neutropenia.
ナラティブ更新 • Apr 20

XFOR: CXCR4 Program In WHIM And Chronic Neutropenia Will Drive Future Upside

Analysts have reset their price target on X4 Pharmaceuticals to $12, citing Guggenheim's recent initiation, which highlights mavorixafor as a key value driver in WHIM syndrome and primary chronic neutropenia. Analyst Commentary The latest Street research frames X4 Pharmaceuticals as closely tied to the success of mavorixafor in WHIM syndrome and primary chronic neutropenia.
ナラティブ更新 • Apr 05

XFOR: Mavorixafor Franchise Is Expected To Drive Future Upside Potential

Narrative Update Analysts have raised their price target for X4 Pharmaceuticals to $12, citing the perceived upside in mavorixafor as a key value driver and updating fair value assumptions to $10.00, along with adjusted growth, margin, discount rate, and future P/E inputs. Analyst Commentary Recent research points to mavorixafor as the central piece of the X4 Pharmaceuticals story, with coverage initiating at a $12 price target that aligns with the view of the drug as a key value driver.
ナラティブ更新 • Mar 22

XFOR: WHIM And Chronic Neutropenia Program Will Drive Future Upside

Analysts have adjusted their price target on X4 Pharmaceuticals to $12, noting what they view as potential upside tied to mavorixafor as a key value driver in WHIM syndrome and primary chronic neutropenia. Analyst Commentary Recent commentary from bullish analysts centers on how mavorixafor could reshape the risk reward profile for X4 Pharmaceuticals, especially as the program advances in WHIM syndrome and primary chronic neutropenia.
ナラティブ更新 • Mar 07

XFOR: EU WHIM Decision And Chronic Neutropenia Program Will Drive Upside Potential

Analysts have reset their price target for X4 Pharmaceuticals to $13.00, reflecting updated assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E that they see as better aligned with the company’s current risk and earnings profile. What's in the News The European Medicines Agency's CHMP adopted a positive opinion recommending marketing authorization, under exceptional circumstances, for mavorixafor to treat WHIM syndrome in the EU (Key Developments).
ナラティブ更新 • Feb 21

XFOR: Higher Fair Value Will Reflect Stronger Outlook Despite Margin Headwinds

Analysts have lifted their fair value estimate for X4 Pharmaceuticals from $4.00 to $5.00 per share, citing updated assumptions around the discount rate, revenue growth, profit margin, and future P/E as key drivers of the new price target. Valuation Changes Fair Value was raised from $4.00 to $5.00 per share, an increase of 25% in the modelled estimate.
ナラティブ更新 • Feb 06

XFOR: Fair Value View Will Balance Dilution Concerns And Execution Milestones

Analysts have lifted their price target on X4 Pharmaceuticals to $4.00 per share from $4.00, citing updated assumptions around revenue growth, discount rate, profit margin, and future P/E that are now reflected in their models. Valuation Changes Fair Value: Maintained at $4.00 per share, with no change from the prior estimate.
ナラティブ更新 • Jan 23

XFOR: Future Outlook Weighs October Financing Dilution Against Execution And Earnings Milestones

Narrative Update Analysts have trimmed their 12 month price target on X4 Pharmaceuticals to US$7.50 from US$9.00, mainly reflecting updated financing assumptions after the recent earnings report and the October capital raise. Analyst Commentary Bearish analysts are using the latest earnings report and the October capital raise to reset expectations on X4 Pharmaceuticals, with the 12 month price target update to US$7.50 at the center of their view.
ナラティブ更新 • Jan 09

XFOR: Future Outlook Balances October Financing Dilution With Execution And Earnings Milestones

Analysts have trimmed their 12 month price target for X4 Pharmaceuticals to US$7.50 from US$9.00, citing updated financing assumptions following the October capital raise as well as recent earnings and corporate updates. Analyst Commentary Bearish analysts are framing the lower US$7.50 12 month price target as a reset that reflects updated expectations after recent earnings and the October capital raise.
分析記事 • Dec 24

X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) Shares May Have Run Too Fast Too Soon

With a median price-to-sales (or "P/S") ratio of close to 12.4x in the Biotechs industry in the United States, you...
ナラティブ更新 • Dec 22

XFOR Future Outlook Weighs Financing Dilution Against Long Term Commercial Upside

Analysts have trimmed their price target on X4 Pharmaceuticals by $1.50 to $7.50, citing updated models that factor in revised financing assumptions following the company’s recent earnings report and October capital raise. Analyst Commentary Bearish analysts have pointed to the latest target cut as evidence that X4 Pharmaceuticals faces a more challenging path to value creation than previously modeled, with revised financing assumptions weighing on upside potential.
ナラティブ更新 • Dec 07

XFOR: Recent Financing Will Support Key Phase 3 Progress And Upside Potential

Analysts have modestly trimmed their fair value estimate for X4 Pharmaceuticals, cutting the price target from $9.00 to $7.50, as updated models incorporate revised financing assumptions following the company's recent capital raise. Analyst Commentary Analyst updates following the latest earnings report and corporate update emphasize that the lower price target is primarily a function of revised financing assumptions rather than a fundamental shift in the long term outlook for X4 Pharmaceuticals.
ナラティブ更新 • Nov 23

XFOR: Leadership Overhaul And Fresh Capital Will Drive Pipeline Progress

Analysts have revised their price target for X4 Pharmaceuticals downward from $8.70 to $7.38. They cite updated financing assumptions and recent corporate developments as key factors behind the adjustment.
ナラティブ更新 • Sep 25

US Launch And EMA Approval Will Expand Global Reach

Amid leadership changes and a recapitalization that add near-term execution risk despite long-term potential for mavorixafor in a substantial unmet market, analysts have lowered their price target for X4 Pharmaceuticals from $19.75 to $8.70. Analyst Commentary Leadership overhaul and new senior management introduce execution uncertainty but may improve strategic direction.
ナラティブ更新 • Sep 02

US Launch And EMA Approval Will Expand Global Reach

Analysts have lowered their price target for X4 Pharmaceuticals from $23.25 to $19.75, citing increased execution risks and near-term uncertainty from a leadership overhaul, tempered by optimism over recent recapitalization and the long-term potential of mavorixafor. Analyst Commentary Recent complete overhaul of the senior leadership team introduces uncertainty but also the potential for strategic renewal.
ナラティブ更新 • Aug 19

US Launch And EMA Approval Will Expand Global Reach

A significant reduction in X4 Pharmaceuticals’ future P/E signals lower growth expectations or improved earnings outlook, while a decreased discount rate indicates lower perceived risk, contributing to a sharp downward revision in the fair value estimate from $41.08 to $23.25. What's in the News X4 Pharmaceuticals completed a private placement, issuing 11,040,776 shares at $1.42 and 48,852,772 pre-funded warrants at $1.419, raising $85 million, led by Coastlands Capital LP and supported by top life science investors.
分析記事 • Aug 12

X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) Revenues Are Not Doing Enough For Some Investors

You may think that with a price-to-sales (or "P/S") ratio of 0.3x X4 Pharmaceuticals, Inc. ( NASDAQ:XFOR ) is...
User avatar
新しいナラティブ • Mar 30

US Launch And EMA Approval Will Expand Global Reach

The transition to a commercial-stage pharmaceutical and strategic international partnerships could significantly boost revenue growth and international market presence.
Seeking Alpha • Jul 02

X4 Pharmaceuticals: Catch The Falling Knife After Propitious Mavorixafor Data

Summary X4 Pharmaceuticals, Inc. stock price dropped due to the discontinuation of Phase II study for chronic neutropenia, but the potential market for mavorixafor is substantial. X4 Pharmaceuticals is targeting rare diseases with mavorixafor, approved for WHIM syndrome, and moving forward with a Phase III trial for CN. X4 Pharmaceuticals has the potential for significant growth with mavorixafor addressing multiple rare diseases, but faces risks including FDA approval and market penetration. I discuss why I am attempting to "catch the falling knife." Read the full article on Seeking Alpha
分析記事 • Mar 26

Is X4 Pharmaceuticals (NASDAQ:XFOR) Weighed On By Its Debt Load?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
分析記事 • Apr 19

Is X4 Pharmaceuticals (NASDAQ:XFOR) A Risky Investment?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
分析記事 • Oct 07

Is X4 Pharmaceuticals (NASDAQ:XFOR) Using Too Much Debt?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

決済の安定と成長

配当データの取得

安定した配当: XFORの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。

増加する配当: XFORの配当金が増加しているかどうかを判断するにはデータが不十分です。

配当利回り対市場

X4 Pharmaceuticals 配当利回り対市場
XFOR 配当利回りは市場と比べてどうか？
セグメント配当利回り
会社 (XFOR)n/a
市場下位25% (US)1.3%
市場トップ25% (US)4.1%
業界平均 (Biotechs)2.2%
アナリスト予想 (XFOR) (最長3年)n/a

注目すべき配当: XFORは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。

高配当: XFORは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。

株主への利益配当

収益カバレッジ: XFORの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。

株主配当金

キャッシュフローカバレッジ: XFORが配当金を報告していないため、配当金の持続可能性を計算できません。

高配当企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/07/21 14:20
終値2026/07/21 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

X4 Pharmaceuticals, Inc. 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。10

アナリスト機関
Leah Rush CannBrookline Capital Markets
Arlinda LeeCanaccord Genuity
Michael SchmidtGuggenheim Securities, LLC